Navigation Links
Atherotech Receives Patent for ApoB Measurement
Date:5/19/2009

tes, high blood pressure or heart disease - or who are already taking cholesterol lowering medication - are candidates for the comprehensive VAP Test, according to Atherotech President Mike Mullen.

"The single VAP Test reports over 20 separate values, including apoB, eliminating the need for nine separate tests that would have to be run in a typical laboratory setting," commented Mullen. "The VAP Test is now well positioned to be the market leader in advanced lipid testing. It has the comprehensive lipid reporting that an increasing number of physicians and practices are requesting without the added cost, which fits nicely in our current economic and health care environment."

Mullen said the patent should have a positive impact on his company's business.

"We expect to see an increase in orders for our VAP Test because of its clinically validated ability to accurately report apoB and because it is quickly becoming more of a standard in determining heart disease risk in cholesterol testing."

The VAP Test is available nationwide and covered by most insurance providers, including Medicare and Medicaid. For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert
'/>"/>

SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia
2. Atherotech Unveils New Cardiometabolic Test Panels
3. Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
4. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
5. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
6. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
7. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
8. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
9. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
10. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
11. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... 16 CEL-SCI Corporation (NYSE Amex: ... prevention and treatment of infectious diseases and a late-stage oncology ... (FDA) has indicated that the Company can proceed with its ... LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 ...
... , , EAST BRUNSWICK, N.J. Sept. 16 ... on September 14, 2009, the Company completed a Type A meeting with ... Letter (CRL) received by Savient on July 31, 2009 regarding the Company,s ... gout in patients refractory to conventional therapy. , ...
... ... FDA, including increased scrutiny of complex medical devices, automating your QA process is more ... one of the leading medical device software engineering and QA consulting firms in the ... , ...
Cached Biology Technology:CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 2CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 2Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 3Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 5Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 6Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... new studies shed light on the complex defense mechanisms ... of which could lead to new, more effective antibiotics ... of antibiotic resistance. The studies, both of which target ... will appear in the February 17 inaugural print issue ...
... San Francisco, is just one of the many American ... trial in India. , The trial is studying ... Under Guidance): a reversible, nonhormonal contraceptive that provides 10 ... procedure. Researchers received approval this week to begin enrolling ...
... at just four months old, babies are able to ... according to brightness, shape, and how close the visual ... very young infants are much more capable of organising ... The study also has implications for understanding certain developmental ...
Cached Biology News:Pair of studies offer new clues to combat antibiotic resistance 2New male contraceptive clears hurdle 2New male contraceptive clears hurdle 3Infants can organise visual information at just four months 2Infants can organise visual information at just four months 3
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Biology Products: